USFDA Inspection at Concord Biotech Ltd's API facility at Dholka

Concord Biotech Limited has announced the completion of the inspection of its API facility at Dholka. The inspection took place from April 28 to May 2, 2025.

At the conclusion of the inspection, the USFDA issued Form 483 with four observations. According to the Company, these observations are procedural in nature and none of them are related to data integrity.

The Company states that it will provide a detailed response to the USFDA within the required timeframe and is confident of addressing the observations expeditiously.

Shares of Concord Biotech Limited was last trading in BSE at Rs. 1493.25 as compared to the previous close of Rs. 1524.25. The total number of shares traded during the day was 6429 in over 694 trades.

The stock hit an intraday high of Rs. 1531.95 and intraday low of 1477.05. The net turnover during the day was Rs. 9610216.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 USFDA Inspection APIFacility Dholka Form483 4Observations